RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PLANCHARD D
Collezione AOU San Luigi di Orbassano

Items : 9

Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2025 Jan 17;31(2):352-364. doi: 10.1158/1078-0432.CCR-24-1993.

2025
AOU San Luigi di Orbassano

Dall'Olio FG; Zrafi W; Roelants V; Ambrosini V; Fourquet A; Mitea C; Passiglia F; Bauckneht M; Bonardel G; Conci N; Benitez JC; Arena V; Namour C; Naigeon M; Monnet I; Beshiri K; Hoton D; Dursun S; Danlos FX; Argalia G; Aldea M; Rovera G; Derosa L; Iebba V; Gietema HA; Gounant V; Lacroix V; Remon J; Gautheret D; et alii...

Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2024 Jan;19(1):166-172. doi: 10.1016/j.jtho.2023.08.004. Epub 2023 Aug 9.

2024
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Planchard D; Besse B; Novello S; Barlesi F; Le Péchoux C; Facchinetti F; Aldea M; Genova C; Bironzo P; Di Maio M; Remon J; Tagliamento M; Tagliamento M; Di Maio M; Remon J; Bironzo P; Genova C; Facchinetti F; Aldea M; Le Péchoux C; Novello S; Barlesi F; Besse B; Planchard D;

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Nov 1;41(31):4852-4863. doi: 10.1200/JCO.23.01361. Epub 2023 Sep 11.

2023
AOU San Luigi di Orbassano

Goto K; Goto Y; Kubo T; Ninomiya K; Kim SW; Planchard D; Ahn MJ; Smit EF; de Langen AJ; Pérol M; Pons-Tostivint E; Novello S; Hayashi H; Shimizu J; Kim DW; Kuo CH; Yang JC; Pereira K; Cheng FC; Taguchi A; Cheng Y; Feng W; Tsuchihashi Z; Jänne PA;

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2023 May;18(5):576-586. doi: 10.1016/j.jtho.2022.12.018. Epub 2023 Jan 13.

2023
AOU San Luigi di Orbassano

Aldea M; Marinello A; Duruisseaux M; Zrafi W; Conci N; Massa G; Metro G; Monnet I; Gomez Iranzo P; Tabbo F; Bria E; Guisier F; Vasseur D; Lindsay CR; Ponce-Aix S; Cousin S; Citarella F; Fallet V; Minatta JN; Eisert A; de Saint Basile H; Audigier-Valette C; Mezquita L; Calles A; Mountzios G; Tagliamento M; Remon Masip J; Raimbourg J; Terrisse S; et alii...

How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). in Cancer treatment reviews / Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31.

2022
AOU San Luigi di Orbassano

Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S; Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19.

2021
AOU San Luigi di Orbassano

Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; et alii...

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 May;31(5):609-618. doi: 10.1016/j.annonc.2020.02.006. Epub 2020 Feb 20.

2020
AOU San Luigi di Orbassano

Planchard D; Reinmuth N; Orlov S; Fischer JR; Sugawara S; Mandziuk S; Marquez-Medina D; Novello S; Takeda Y; Soo R; Park K; McCleod M; Geater SL; Powell M; May R; Scheuring U; Stockman P; Kowalski D;

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.

2018
AOU San Luigi di Orbassano

Planchard D; Popat S; Kerr K; Novello S; Smit EF; Faivre-Finn C; Mok TS; Reck M; Van Schil PE; Hellmann MD; Peters S;

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2010 Jun;68(3):420-6. doi: 10.1016/j.lungcan.2009.07.011. Epub 2009 Aug 18.

2010
AOU San Luigi di Orbassano

Scagliotti GV; Germonpré P; Bosquée L; Vansteenkiste J; Gervais R; Planchard D; Reck M; De Marinis F; Lee JS; Park K; Biesma B; Gans S; Ramlau R; Szczesna A; Makhson A; Manikhas G; Morgan B; Zhu Y; Chan KC; von Pawel J;